Karyopharm Therapeutics I...

7.24
-0.71 (-8.93%)
At close: Mar 03, 2025, 3:59 PM
7.61
5.11%
After-hours: Mar 03, 2025, 04:01 PM EST

Karyopharm Therapeutics Statistics

Share Statistics

Karyopharm Therapeutics has 8.42M shares outstanding. The number of shares has increased by 9.67% in one year.

Shares Outstanding 8.42M
Shares Change (YoY) 9.67%
Shares Change (QoQ) 1.21%
Owned by Institutions (%) 47.52%
Shares Floating 7.75M
Failed to Deliver (FTD) Shares 12.38K
FTD / Avg. Volume 15.64%

Short Selling Information

The latest short interest is 19.8M, so 15.69% of the outstanding shares have been sold short.

Short Interest 19.8M
Short % of Shares Out 15.69%
Short % of Float 16.98%
Short Ratio (days to cover) 17.52

Valuation Ratios

The PE ratio is -16.17 and the forward PE ratio is -0.89. Karyopharm Therapeutics's PEG ratio is 0.33.

PE Ratio -16.17
Forward PE -0.89
PS Ratio 8.51
Forward PS 0.2
PB Ratio -6.64
P/FCF Ratio -9.68
PEG Ratio 0.33
Financial Ratio History

Enterprise Valuation

Karyopharm Therapeutics Inc. has an Enterprise Value (EV) of 222.93M.

EV / Earnings -2.92
EV / Sales 1.53
EV / EBITDA -5.77
EV / EBIT -1.87
EV / FCF -1.75

Financial Position

The company has a current ratio of 1.7, with a Debt / Equity ratio of -0.54.

Current Ratio 1.7
Quick Ratio 1.64
Debt / Equity -0.54
Total Debt / Capitalization -116.06
Cash Flow / Debt -1.28
Interest Coverage -3.19

Financial Efficiency

Return on equity (ROE) is 0.41% and return on capital (ROIC) is 138.84%.

Return on Equity (ROE) 0.41%
Return on Assets (ROA) -0.46%
Return on Capital (ROIC) 138.84%
Revenue Per Employee $520,562.72
Profits Per Employee $-273,913.98
Employee Count 279
Asset Turnover 0.88
Inventory Turnover 1.27

Taxes

Income Tax 57K
Effective Tax Rate 0

Stock Price Statistics

The stock price has increased by -55.26% in the last 52 weeks. The beta is 0.06, so Karyopharm Therapeutics's price volatility has been higher than the market average.

Beta 0.06
52-Week Price Change -55.26%
50-Day Moving Average 12.22
200-Day Moving Average 12.89
Relative Strength Index (RSI) 47.81
Average Volume (20 Days) 79.11K

Income Statement

In the last 12 months, Karyopharm Therapeutics had revenue of 145.24M and earned -76.42M in profits. Earnings per share was -0.63.

Revenue 145.24M
Gross Profit 139.23M
Operating Income -119.44M
Net Income -76.42M
EBITDA -38.6M
EBIT -119.44M
Earnings Per Share (EPS) -0.63
Full Income Statement

Balance Sheet

The company has 62.48M in cash and 99.92M in debt, giving a net cash position of -37.45M.

Cash & Cash Equivalents 62.48M
Total Debt 99.92M
Net Cash -37.45M
Retained Earnings -1.56B
Total Assets 164.42M
Working Capital 64.23M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -127.49M and capital expenditures -142K, giving a free cash flow of -127.63M.

Operating Cash Flow -127.49M
Capital Expenditures -142K
Free Cash Flow -127.63M
FCF Per Share -1.05
Full Cash Flow Statement

Margins

Gross margin is 95.86%, with operating and profit margins of -82.24% and -52.62%.

Gross Margin 95.86%
Operating Margin -82.24%
Pretax Margin -52.58%
Profit Margin -52.62%
EBITDA Margin -26.58%
EBIT Margin -82.24%
FCF Margin -87.88%

Dividends & Yields

KPTI does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield -7.92%
FCF Yield -190.75%
Dividend Details

Analyst Forecast

The average price target for KPTI is $65.5, which is 723.9% higher than the current price. The consensus rating is "Buy".

Price Target $65.5
Price Target Difference 723.9%
Analyst Consensus Buy
Analyst Count 4
Stock Forecasts

Stock Splits

The last stock split was on Feb 26, 2025. It was a backward split with a ratio of 1:15.

Last Split Date Feb 26, 2025
Split Type backward
Split Ratio 1:15

Scores

Altman Z-Score -10.88
Piotroski F-Score 3